Discovering The Potential of PIAS1 in Cancer Treatment (G8554)

Target Name: PIAS1

NCBI ID: G8554

PIAS1

Discovering The Potential of PIAS1 in Cancer Treatment

PIAS1 (Promyelocytic leukemia- associated protein 1) is a protein that is expressed in various tissues of the human body, including the brain, spleen, and bone marrow. It is a member of the PIAS family of proteins, which are known for their role in cell signaling and inflammation.

One of the unique features of PIAS1 is its ability to induce cell death, either through apoptosis or through a process called "cross-talk," which involves the inhibition of the expression of neighboring genes. This makes PIAS1 a very attractive drug target because scientists can treat many diseases by inhibiting PIAS1 function.

Recently, researchers have discovered the potential of PIAS1 in treating cancer, specifically leukemia. Leukemia is a malignant disease of the blood system that usually causes abnormal proliferation of white blood cells, leading to immune system overload, organ function damage, and death.

To better understand the role of PIAS1 in leukemia treatment, scientists conducted a variety of experiments. They found that PIAS1 can inhibit the production of new cells in leukemia patients, thereby inhibiting the growth of cancer cells. They also found that PIAS1 can regulate the activity of immune cells in leukemia patients, thereby enhancing the anti-cancer effect of the immune system.

In addition to treating leukemia, PIAS1 may also have potential applications in treating other cancers. For example, scientists have found that PIAS1 can inhibit the growth of liver cancer and testicular cancer, thus providing new ideas for the treatment of these two cancers.

Still, PIAS1 remains a very attractive drug target because scientists have found that it may be involved in many other diseases. For example, scientists have found that PIAS1 is involved in the pathogenesis of Parkinson's disease and is associated with neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

In addition, PIAS1 is also related to mental health. Research has shown that PIAS1 is associated with mental health problems such as depression and anxiety, and may be related to disease risk and treatment response.

Therefore, PIAS1 is a very attractive drug target and can provide new ideas for the treatment of many diseases. Future research will continue to further explore the role of PIAS1 in drug discovery and treatment, bringing more benefits to human health.

Protein Name: Protein Inhibitor Of Activated STAT 1

Functions: Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. In vitro, binds A/T-rich DNA. The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context. Sumoylates PML (at'Lys-65' and 'Lys-160') and PML-RAR and promotes their ubiquitin-mediated degradation. PIAS1-mediated sumoylation of PML promotes its interaction with CSNK2A1/CK2 which in turn promotes PML phosphorylation and degradation (By similarity). Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation. Plays a dynamic role in adipogenesis by promoting the SUMOylation and degradation of CEBPB (By similarity)

The "PIAS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PIAS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets